Core Points - Kintara Therapeutics has adjourned its Special Meeting of Stockholders due to not reaching the voting threshold for Proposals 3 and 5, which are related to increasing authorized shares and reincorporation from Nevada to Delaware [2][3] - The Special Meeting will reconvene on October 4, 2024, at 9:00 a.m. Eastern Time [1] - The record date for stockholders entitled to vote remains August 14, 2024, and previously submitted proxies will be voted at the adjourned meeting unless revoked [3] Company Overview - Kintara Therapeutics is focused on developing novel cancer therapies, particularly for patients with unmet medical needs, with its lead program being REM-001 Therapy for cutaneous metastatic breast cancer [6][7] - The company utilizes a proprietary photodynamic therapy platform, which has shown an 80% clinical efficacy in complete responses for evaluable lesions in CMBC patients [7] - Kintara is headquartered in San Diego, California, and aims to address significant medical needs with reduced risk development programs [6][8] Proposed Merger - Kintara is in the process of a proposed merger with TuHURA Biosciences, which is developing immuno-oncology technologies to overcome resistance to cancer therapies [2][4] - TuHURA's lead product candidate, IFx-2.0, is designed to enhance the effectiveness of checkpoint inhibitors in treating advanced or metastatic Merkel Cell Carcinoma [4] - The merger is contingent upon stockholder approval and the completion of necessary regulatory filings with the SEC [11][12]
Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024